Investor Centre

Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
Stat background
3.91 GBX Volume: 1,417,061 Market Capitalisation (m) £10.75

Investor Meet and ProActive Investor Events

23 - March - 2023
Latest corporate presentation following Investor Meet Company and ProActive Investor Events on 23 March 2023.

Stalicla Licensing Deal

10 - October - 2022
Evgen Pharma has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla

Evgen Investor Meet Company Presentation

23 - March - 2023
CEO Dr Huw Jones and CMO Dr Glen Clack provide an update following publication of the preliminary results from the phase 1b study.
Company Analyst
finnCap Mark Brewer

Major Shareholder

Current StakeholderNumber of sharesPercentage holding
J. R. Kight33,100,00012.0%
AXA Framlington23,848,8848.7%
Octopus Investments21,875,0008.0%
SPARK Impact16,186,4465.9%
Seneca Investment Managers14,932,0715.4%
Chelverton Asset Management12,500,0004.5%
RAB Capital8,750,0003.2%
Newlands Capital8,314,8153.0%
The number of ordinary shares in issue is 274,888,117 all of which are in public hands. The Company does not hold any shares in Treasury.
Last updated 24 October 2022